TCGA-85-7699-01A-11R-2125-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.660
- E2F_TARGETS+0.640
- MYC_TARGETS_V1+0.530
- MITOTIC_SPINDLE+0.510
- MYC_TARGETS_V2+0.500
- WNT_BETA_CATENIN_SIGNALING+0.440
- ALLOGRAFT_REJECTION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- DNA_REPAIR+0.340
- APICAL_SURFACE+0.320
Top 10 suppressed
- COAGULATION-0.340
- XENOBIOTIC_METABOLISM-0.320
- BILE_ACID_METABOLISM-0.300
- FATTY_ACID_METABOLISM-0.240
- MYOGENESIS-0.210
- PANCREAS_BETA_CELLS-0.200
- INTERFERON_ALPHA_RESPONSE-0.180
- HEME_METABOLISM-0.170
- KRAS_SIGNALING_DN-0.170
- PEROXISOME-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-90-7767-01A-11R-2125-07 | — | cohortSQ1 | 0.860 |
| 2 | SRR934900 | — | — | 0.840 |
| 3 | SRR934902 | — | — | 0.824 |
| 4 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.806 |
| 5 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.802 |
| 6 | SRR934813 | — | — | 0.799 |
| 7 | 3DA19761-6FF3-4E8C-AA0F-C04CE2CE7037 | — | — | 0.795 |
| 8 | MDT-AP-3334 | Med | Medulloblastoma | 0.794 |
| 9 | SRR934748 | — | — | 0.794 |
| 10 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.660 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.640 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |